A Fatal Case of Life-Threatening Interstitial Pneumonitis Induced by Everolimus for Metastatic Renal Cell Carcinoma: A Comment about the Increased Risk of Interstitial Lung Disease in Japanese

Table 1

Comparison of previous studies regarding interstitial lung disease associated with TKI or mTOR inhibitor in Japanese patients with renal cell carcinoma and lung cancer.

				% of ILD
Series	Type of cancer	Type of drug	n	All grades	Grade 3/4	Grade 5
Mizuno et al. [3]	RCC	mTOR inhibitor (Everolimus)	11	63.6	36.3	0
Mikami et al. [14]	RCC	mTOR inhibitor (Everolimus)	16	31	0	0
Akamatsu et al. [15]	NSCLC	TKI (Gefetinib)	201	5	2.5	1
Nakagawa et al. [16]	NSCLC	TKI (Erlotinib)	3488	4.5	2.6	1.6
Ando et al. [13]	NSCLC	TKI (Gefetinib)	1976	3.5	1.9	1.6

RCC, renal cell carcinoma; NSCLC, nonsmall cell lung carcinoma; ILD, interstitial lung disease; mTOR, mammalian target of rapamycin; TKI, tyrosine kinase inhibitor.